learn Baricitinib
JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases
Search
forLearn
5 / 801 resultslearn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn Mesotherapy
technique to inject very small amounts of beneficial chemicals into the scalp
learn 18β-glycyrrhetinic acid
learn phenoxyethanol
Research
5 / 1000+ results
research Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure.
A stable and simple finasteride suspension was developed that retains over 94.3% of its concentration for up to 90 days and doesn't significantly increase occupational exposure, but safety measures are still advised.
research EXPLORING THE ROLE OF UMBILICAL CORD AND CORD BLOOD IN REGENERATIVE MEDICINE
Umbilical cord and cord blood stem cells are promising for treating chronic diseases due to their versatility and ethical acceptability.
research Toxicity of the pharmaceuticals finasteride and melengestrol acetate to benthic invertebrates
Finasteride harms invertebrates' survival and burial ability.
research Pharmaceutical evaluation of different shampoo brands in local Saudi market
All evaluated shampoos meet Saudi standards.
research Formulation and Evaluation of Herbal Hair Gel
The herbal hair gel is effective, eco-friendly, and non-irritating with antifungal properties.
Community Join
5 / 1000+ resultscommunity Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
community Kintor Pharmaceutical’s KX-826 Shows Promising Results in Hair Loss Study
Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.
community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
community JW Pharmaceutical shows superiority of 'JW0061' in hair growth over existing treatments in US
JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.
community Kintor Pharmaceutical Announced U.S. FDA Has Greenlighted Phase II Clinical Trial for Pyrilutamide to Treat Androgenetic Alopecia
Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.